Prevalence of Aspirin Resistance in Patients with Transcatheter Pulmonary Valve Replacement

• DOI: 10.1002/ccd.31440
• Publication Date: 2025-02-11T08:22:42Z
• Authors: Alex Sigman; Emily Riley; Trudy Pierick; Osamah Aldoss; Prashob Porayette

ABSTRACT Background Congenital heart disease (CHD) patients with pulmonary valve failure may undergo transcatheter replacement (TPVR). Aspirin is often prescribed as long‐term therapy after TPVR to prevent thromboembolic events (TE). Aims We aimed examine the prevalence of aspirin resistance within CHD population. Methods The VerifyNow point‐of‐care test quantifies platelet aggregation Reactivity Units (ARU). ARU values greater than 550 suggest (AR). A retrospective chart review analyzed results from May 2022 through December 2023 in following successful ( n = 48). Lifelong TE history was collected. Association between AR and sex, race, ethnicity examined Fisher's Exact test, Wilcoxon rank sum exact associations age. Results Three 45 (6.67%) aspirin‐compliant (average age 33.14 years; range 0.74−77.86 years, 47% females) were AR. Interestingly, all females, suggesting higher females p 0.094). No significant found 0.8), race 0.077), or 0.2). had a documented TE. Five 42 (11.9%) sensitive while taking aspirin, including two (not on birth control at time event) three males. Conclusions prevalent patients, but occurrence did not correlate However, exclusively suggests need for further investigations most effective prophylaxis this